Company Description
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally.
The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development.
Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers.
Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
| Country | United States |
| Founded | 1976 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Kara Cannon |
Contact Details
Address: 21 Executive Blvd Farmingdale, New York 11735 United States | |
| Phone | 631 755 5500 |
| Website | enzo.com |
Stock Details
| Ticker Symbol | ENZ |
| Exchange | NYSE |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0000316253 |
| CUSIP Number | 294100102 |
| ISIN Number | US2941001024 |
| Employer ID | 13-2866202 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kara Cannon | Chief Executive Officer and Director |
| Patricia Eckert CPA | Chief Financial Officer |
| Brian J. Fisher | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 10-K | Annual Report |
| Sep 24, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 2, 2024 | 8-K | Current Report |
| Jul 25, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 13, 2024 | 10-Q | Quarterly Report |
| May 24, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |